Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Royalty Pharma Plc Cl A (NQ: RPRX ) 26.91 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 26.91 Bid (Size) 26.16 (12) Ask (Size) 27.00 (1) Prev. Close 26.91 Today's Range 26.91 - 26.91 52wk Range 25.92 - 31.66 Shares Outstanding 388,132,400 Dividend Yield 2.97% Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields June 12, 2024 Via Benzinga June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge June 05, 2024 Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. Via InvestorPlace Performance YTD -4.81% -4.81% 1 Month +1.09% +1.09% 3 Month -11.13% -11.13% 6 Month -1.21% -1.21% 1 Year -10.42% -10.42% More News Read More Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes June 03, 2024 From Royalty Pharma plc Via GlobeNewswire NASDAQ:RPRX: good value for what you're paying. April 24, 2024 Via Chartmill Looking Into Royalty Pharma's Recent Short Interest April 04, 2024 Via Benzinga NASDAQ:RPRX is an undervalued gem with solid fundamentals. March 29, 2024 Via Chartmill Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? May 28, 2024 Via Benzinga Exposures Product Safety Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out May 28, 2024 Via Investor's Business Daily Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million May 28, 2024 From Royalty Pharma plc Via GlobeNewswire Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe May 23, 2024 Via Benzinga Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline May 22, 2024 From Royalty Pharma plc; Cytokinetics Via GlobeNewswire 7 Dividend Stocks to Buy at a 52-Week Low May 20, 2024 Via InvestorPlace Royalty Pharma to Present at Upcoming Investor Conferences May 13, 2024 From Royalty Pharma plc Via GlobeNewswire RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Royalty Pharma Reports First Quarter 2024 Results May 09, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab May 09, 2024 From Royalty Pharma plc Via GlobeNewswire Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment May 02, 2024 Via Benzinga Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 April 19, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Declares Second Quarter 2024 Dividend April 17, 2024 From Royalty Pharma plc Via GlobeNewswire 3 Pharma Stocks to Sell in April Before They Crash & Burn April 11, 2024 Via InvestorPlace Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of) April 09, 2024 Via InvestorPlace April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio April 09, 2024 Via InvestorPlace The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio March 27, 2024 Via InvestorPlace For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals. February 29, 2024 Via Chartmill Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.